- Asia Pacific
- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Recent Pfizer Press Releases
5/30/07 4:47 am EDT
Smokers in the UK Should Now Have Access to ChampixNEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for use on the National Health Service for adult smokers who have expressed a desire to quit. This gives smokers across England, Wales and Northern Ireland access to another important treatment option to help them quit smoking. In its Final Appraisalmore...
5/29/07 11:42 am EDTNEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Monday, June 4, at 6:00 p.m. Central Daylight Savings Time, in connection with the Annual Meeting of the American Society of Clinical Oncology (ASCO). The analyst meeting will include presentations by Pfizer’s oncology leadership team. To view the webcast, visit our web sitemore...
5/29/07 11:41 am EDT--(BUSINESS WIRE)--At next week’s American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of its oncology portfolio and the significant potential of projects advancing through the company’s research and development pipeline. Note: Details about key Pfizer presentations at ASCO are in the accompanying press release. Pfizer’s R&D pipeline inmore...
5/29/07 11:39 am EDT
Company Expands Phase III Research Program Evaluating SUTENT in Metastatic Breast CancerNEW YORK--(BUSINESS WIRE)--Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC) and renal cell carcinoma (RCC) – a type of advanced kidney cancer – will be presented next week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. “Each person with cancer responds differently to treatmentmore...
5/29/07 10:19 am EDT
Decision has no bearing on Lipitor patent challenges in other countriesNEW YORK--(BUSINESS WIRE)--Pfizer Inc. said today that it will immediately seek to appeal a ruling by the Borgarting Court of Appeal in Oslo, Norway that four of Pfizer’s patents covering Lipitor are either invalid or not infringed by a proposed generic atorvastatin calcium product from Ranbaxy Laboratories. The Supreme Court of Norway will determine whether to hear the appeal. The Court of Appeal ruled that three Pfizer patents coveringmore...
5/26/07 10:11 pm EDTRIO VISTA, Calif.--(BUSINESS WIRE)--Responding to a request from the Marine Mammal Center, Pfizer Animal Health (PAH) has donated an antibiotic which was used today to treat the two humpback whales lost and injured in the Sacramento River. "We hope mother and baby recover and find their way home," said Christina Dougherty, VMD, Senior Veterinarian, Pfizer Animal Health. Pfizer veterinarians have been working with veterinarians from the Marinemore...
Pfizer Supports Complete Smoking Ban in Public Areas and Improved Access to Smoking Cessation Treatments across Europe5/24/07 4:00 am EDT
Smoking Causes 15% of EU Deaths
Daily cost of Cardiovascular Diseases estimated €463 Million
May 31st “World No Tobacco Day”BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) (LSE:PFZ) welcomes the European Commission’s Green Paper on smoke free environments1, which was put for public consultation earlier this year. Today in Brussels, a week before World No Tobacco Day (May 31st), the world’s leading life sciences company submitted its recommendations on the questions raised in the Commission’s Paper. The Consultation will conclude on June 1stmore...
5/20/07 9:25 pm EDT
Company to Focus on Accelerating Development and Commercialization
of Strong Early- and Mid-Stage Pipeline
Pfizer Also Announces Resignation of Chief Financial Officer
Alan Levin, Who Will Continue as CFO Until Successor is NamedNEW YORK--(BUSINESS WIRE)--Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company’s research division throughout his 30-year career, will retire from Pfizer by the end of this year. The company will begin a search both inside and outside the company for his successor, and Dr. LaMattina has agreed to remain during this period to ensure a smoothmore...
5/15/07 7:06 pm EDTNEW YORK--(BUSINESS WIRE)--Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle Simon’s breast cancer. The case, Simon vs. Wyeth, et al., was heard in the Philadelphia Court of Common Pleas. “While we have great sympathy for what Mrs. Simon and her family have been through, today’s verdict is neither supported by the evidence introducedmore...
5/14/07 6:27 am EDTBRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer welcomes the 1st European Parliamentary symposium on pharmaceuticals “Putting an end to drug counter-feiting”, which convened European policy makers, regulators and specialists on counterfeiting and medicines trading in the European Parliament today. “Pfizer is very concerned about the surges in counterfeit medicines, putting at risk the lives and wellbeing of patients inmore...